PMID- 36729850
OWN - NLM
STAT- MEDLINE
DCOM- 20230313
LR  - 20230901
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 34
IP  - 4
DP  - 2023 Apr 1
TI  - Sustained antitumor response to lenvatinib with weekend-off and alternate-day 
      administration in chemotherapy-refractory thymic carcinoma: a case report.
PG  - 605-608
LID - 10.1097/CAD.0000000000001474 [doi]
AB  - Lenvatinib is a multitargeted kinase inhibitor and maintaining its dose intensity 
      has been shown to be beneficial in patients with thyroid and hepatocellular 
      carcinomas. However, most patients require lenvatinib interruption and dose 
      reduction due to the high incidence of adverse events (AEs). Lenvatinib was 
      recently approved in Japan for patients with unresectable thymic carcinoma; 
      however, real-world evidence of its clinical benefit is limited. Here, we report 
      the case of chemotherapy-refractory thymic carcinoma in a patient who was 
      administered a starting dose of lenvatinib using a 5-day on/2-day off 
      (weekend-off) protocol, followed by alternate-day administration after fatigue 
      onset derived from overt or subclinical hypothyroidism. Consequently, the patient 
      exhibited a durable response to lenvatinib, with a 17-month progression-free 
      survival without any severe or intolerable AEs. The present case suggests that 
      maintaining lenvatinib dose intensity using such alternative administration 
      regimens contributes to favorable clinical outcomes in thymic carcinoma.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Sunaga, Noriaki
AU  - Sunaga N
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Miura, Yosuke
AU  - Miura Y
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Sakurai, Reiko
AU  - Sakurai R
AD  - Oncology Center, Gunma University Hospital.
FAU - Ohshima, Sohei
AU  - Ohshima S
AD  - Department of Pharmacy, Gunma University Hospital.
FAU - Uno, Shogo
AU  - Uno S
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Muto, Sohei
AU  - Muto S
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Sato, Mari
AU  - Sato M
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Tsurumaki, Hiroaki
AU  - Tsurumaki H
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Yatomi, Masakiyo
AU  - Yatomi M
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Koga, Yasuhiko
AU  - Koga Y
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Ohtaki, Yoichi
AU  - Ohtaki Y
AD  - Department of General Surgical Science.
FAU - Nagashima, Toshiteru
AU  - Nagashima T
AD  - Department of General Surgical Science.
FAU - Okano, Naoko
AU  - Okano N
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine.
FAU - Kubo, Nobuteru
AU  - Kubo N
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine.
FAU - Maeno, Toshitaka
AU  - Maeno T
AD  - Department of Respiratory Medicine, Gunma University Graduate School of Medicine.
FAU - Hisada, Takeshi
AU  - Hisada T
AD  - Gunma University Graduate School of Health Sciences, Maebashi, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20221205
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
SB  - IM
MH  - Humans
MH  - *Thymoma/drug therapy/chemically induced
MH  - *Antineoplastic Agents/therapeutic use
MH  - Phenylurea Compounds/therapeutic use
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Quinolines/therapeutic use
MH  - *Liver Neoplasms/pathology
MH  - *Thymus Neoplasms/drug therapy/chemically induced
EDAT- 2023/02/03 06:00
MHDA- 2023/03/14 06:00
CRDT- 2023/02/02 12:43
PHST- 2023/02/03 06:00 [pubmed]
PHST- 2023/03/14 06:00 [medline]
PHST- 2023/02/02 12:43 [entrez]
AID - 00001813-202304000-00017 [pii]
AID - 10.1097/CAD.0000000000001474 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2023 Apr 1;34(4):605-608. doi: 10.1097/CAD.0000000000001474. 
      Epub 2022 Dec 5.